Last updated on February 2020

A Study of XmAb 23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)


Brief description of study

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.

Clinical Study Identifier: NCT03752398

Find a site near you

Start Over